Sorrento Therapeutics, Inc. Stock Deutsche Boerse AG
Stocks
8STN
US83587F2020
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 67.15M 58.74M 54.17M 50.12M 95.13M 6.41B 96.72M 649M 254M 3.15B 252M 247M 10.9B | P/E 2021 |
-3.2x | P/E 2022 | -0.65x |
|---|---|---|---|---|---|
| Enterprise Value | 152M 133M 122M 113M 215M 14.48B 218M 1.47B 574M 7.11B 569M 557M 24.63B | EV / Sales 2021 |
29.1x | EV / Sales 2022 | 7.89x |
| Free-Float |
98.65% | Yield 2021 * |
-
| Yield 2022 | - |
| 1 day | +19.20% |
| Manager | Title | Age | Since |
|---|---|---|---|
Henry Ji
CEO | Chief Executive Officer | 61 | 2011-03-31 |
Scott Schaus
CTO | Chief Tech/Sci/R&D Officer | - | 2022-02-28 |
John Waldheim
LAW | General Counsel | - | - |
| Director | Title | Age | Since |
|---|---|---|---|
Henry Ji
CHM | Chairman | 61 | 2017-07-31 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +19.20% | -0.67% | - | - | 816K | |
| -0.70% | -4.77% | +63.00% | +125.03% | 56.98B | |
| +4.91% | -0.19% | +73.70% | +92.14% | 53.58B | |
| +1.48% | +5.97% | +22.59% | +495.47% | 25.63B | |
| -0.59% | -4.68% | -16.82% | -12.99% | 23.51B | |
| +2.43% | +1.06% | +47.70% | -0.11% | 19.43B | |
| -1.65% | +1.93% | +36.57% | -25.46% | 18.12B | |
| -6.84% | +2.18% | +203.03% | +348.11% | 16.46B | |
| +8.74% | +3.51% | +53.81% | - | 14.13B | |
| +1.76% | +2.24% | +29.57% | +195.70% | 14.35B | |
| Average | +2.88% | +0.86% | +57.02% | +152.24% | 26.91B | |
| Weighted average by Cap. | +1.24% | -0.31% | +57.13% | +142.63% |
| 2021 | 2022 | |
|---|---|---|
| Net sales | 52.9M 46.28M 42.68M 39.49M 74.95M 5.05B 76.2M 511M 200M 2.48B 199M 194M 8.59B | 62.84M 54.97M 50.69M 46.9M 89.03M 6B 90.51M 607M 238M 2.95B 236M 231M 10.2B |
| Net income | -428M -375M -346M -320M -607M -40.88B -617M -4.14B -1.62B -20.08B -1.61B -1.57B -69.54B | -573M -501M -462M -428M -812M -54.68B -825M -5.53B -2.17B -26.85B -2.15B -2.1B -93.01B |
| Net Debt | 111M 96.84M 89.3M 82.62M 157M 10.57B 159M 1.07B 419M 5.19B 416M 407M 17.97B | 84.53M 73.94M 68.19M 63.09M 120M 8.07B 122M 817M 320M 3.96B 317M 310M 13.72B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Choose MarketScreener 
